{"analyses":[{"ciLowerLimit":"0.66","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.06","estimateComment":"The HR for atezolizumab plus bevacizumab plus chemotherapy versus bevacizumab plus chemotherapy is provided.","groupDescription":"The study was designed to test the hypothesis that addition of Atezolizumab to Bevacizumab and chemotherapy leads to an increase in median OS from 17 months with Bevacizumab and chemotherapy alone to 24 months. According to the study design, this corresponds to a HR of 0.708. Using the log-rank test stratified by the randomization stratification factors (histological subtype and stage), 284 deaths were required to achieve the trial goal with 82.1% power at a 1-sided significance level of 2.5%.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.14","pValueComment":"1-sided significance level of 2.5%.","paramType":"Hazard Ratio (HR)","paramValue":"0.84","statisticalComment":"Univariate stratified by the randomization stratification factors (histological subtype and stage) Cox for OS with treatment effect only","statisticalMethod":"Regression, Cox"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.5","upperLimit":"23.3","value":"20.5"},{"groupId":"OG001","lowerLimit":"15.7","upperLimit":"20.9","value":"18.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"200"},{"groupId":"OG001","value":"200"}],"units":"Participants"}],"description":"Overall survival is defined as the time from the date of randomisation until death from any cause. Data for patients who are not reported as having died at the date of analysis will be censored at the date when they were last known to be alive. Data for patients without post-baseline information will be censored at the date of randomization (plus 1 day).","dispersionType":"95% Confidence Interval","groups":[{"description":"Atezolizumab 1200mg intravenously on day 1 every 3 weeks plus bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\\^2 intravenously on day 1 every 3 weeks","id":"OG000","title":"Atezolizumab Plus Bevacizumab Plus Chemotherapy"},{"description":"Bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\\^2 intravenously on day 1 every 3 weeks","id":"OG001","title":"Bevacizumab Plus Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"Efficacy population (Intention-To-Treat cohort of all randomised patients)","reportingStatus":"POSTED","timeFrame":"From randomization until death from any cause, up to 52 months.","title":"Overall Survival (OS)","type":"PRIMARY","unitOfMeasure":"months"}